Analysts Rate Adaptimmune Therapeutics plc as a Moderate Buy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has received a consensus rating of "Moderate Buy" from five different brokerages covering the stock, according to recent information. Among these analysts, one has issued a hold recommendation while four have given the stock a buy rating. The average target price for the stock over the next twelve months, based on updates from various brokerages, is $2.18.

Several research analysts have weighed in on Adaptimmune recently. Mizuho has lowered its price target for Adaptimmune shares from $3.00 to $1.50, maintaining an "outperform" rating. This adjustment was noted on November 27th. Additionally, StockNews.com began coverage of Adaptimmune, assigning it a "buy" rating. Wells Fargo & Company also reduced its price target from $2.00 to $1.50, giving it an "equal weight" rating. Finally, Scotiabank decreased its target from $3.15 to $1.40, maintaining a "sector outperform" rating on the stock.

Market Performance of Adaptimmune Therapeutics

On Friday, shares of NASDAQ:ADAP increased by 3.9%, rising by $0.01 to reach a price of $0.29. Approximately 4,999,050 shares were traded, surpassing the average volume of 1,407,286. Adaptimmune has a market capitalization of $74.41 million, a price-to-earnings ratio of -1.32, and a beta of 2.52. The stock's quick ratio stands at 3.82, the current ratio at 3.85, and its debt-to-equity ratio at 0.62. The 50-day moving average for the stock is $0.55, and the 200-day moving average is $0.71. Over the past year, the stock has registered a low of $0.26 and a high of $1.65.

Institutional Investors and Their Recent Activity

Several institutional investors have recently changed their positions in Adaptimmune. Invesco Ltd. increased its stake by 82.0%, owning 63,335 shares valued at $34,000 after acquiring an additional 28,526 shares. Two Sigma Advisers LP saw a significant increase in its holdings by 492.0%, now owning 70,735 shares worth $38,000 after adding 58,787 shares. Similarly, Two Sigma Investments LP raised its stake by 33.5%, holding 76,347 shares valued at $41,000. Virtu Financial LLC also increased its assets in Adaptimmune by 21.5%, now owning 122,696 shares worth $66,000 after acquiring an additional 21,688 shares. Lastly, GSA Capital Partners LLP purchased a new position valued at $95,000 in the third quarter. Overall, about 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a biopharmaceutical company currently in its clinical stage, focusing on providing innovative cell therapies mainly for cancer patients in both the U.S. and the U.K. The company is developing drugs like SPEARHEAD-1, which is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3, which is in phase II trials with ADP-A2M4CD8 for platinum-resistant ovarian cancer; and SURPASS, which is currently undergoing phase I trials for head and neck and urothelial cancers.

Conclusion and Investment Consideration

While Adaptimmune Therapeutics has garnered a "Moderate Buy" rating from analysts, potential investors should evaluate whether this stock fits their investment strategy. Top analysts have indicated other stocks that may be better investment choices at this time. Individuals interested in exploring investment opportunities should carry out thorough research before making decisions.

Adaptimmune, Stocks, Investment